More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What Alzheimer's disease is The difference between Alzheimer's and dementia The ...

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Israel Prize winner Prof. Michal Schwartz says her team's work fighting Alzheimer's can lead to treatments that boost immune ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.